| P50 | author | Nezam Afdhal | Q60650815 |
| | K. Rajender Reddy | Q69932454 |
| | Mark Sulkowski | Q89653950 |
| | Kris V. Kowdley | Q110296712 |
| P2093 | author name string | Andrew Muir | |
| | David R Nelson | |
| | Hongmei Mo | |
| | Ira M Jacobson | |
| | Ming Lin | |
| | Natalie H Bzowej | |
| | Douglas T Dieterich | |
| | Maribel Rodriguez-Torres | |
| | Michael Mader | |
| | William T Symonds | |
| | Efsevia Albanis | |
| | Tarek Hassanein | |
| | Donald Jensen | |
| | Eric Lawitz | |
| | Robert H Hyland | |
| | Bradley Freilich | |
| | Edwin Dejesus | |
| | David E Bernstein | |
| | Gary A Abrams | |
| | Jama M Darling | |
| | Robert Hindes | |
| | Aasim M Sheikh | |
| | Michelle M Berrey | |
| | Fred F Poordad | |
| | Jay P Lalezari | |
| P2860 | cites work | Mechanism of Activation of PSI-7851 and Its Diastereoisomer PSI-7977 | Q24621496 |
| | Review and management of drug interactions with boceprevir and telaprevir | Q24628716 |
| | An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases | Q24632766 |
| | Replication fitness and NS5B drug sensitivity of diverse hepatitis C virus isolates characterized by using a transient replication assay | Q27469483 |
| | Development of Intergenotypic Chimeric Replicons To Determine the Broad-Spectrum Antiviral Activities of Hepatitis C Virus Polymerase Inhibitors | Q27487022 |
| | Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection | Q27860901 |
| | Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose | Q29547886 |
| | Telaprevir for previously untreated chronic hepatitis C virus infection | Q29619800 |
| | Boceprevir for untreated chronic HCV genotype 1 infection | Q29620617 |
| | PSI-7851, a pronucleotide of beta-D-2'-deoxy-2'-fluoro-2'-C-methyluridine monophosphate, is a potent and pan-genotype inhibitor of hepatitis C virus replication | Q34045444 |
| | EASL Clinical Practice Guidelines: management of hepatitis C virus infection | Q34168383 |
| | Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. | Q34320498 |
| | Peginterferon and ribavirin for chronic hepatitis C. | Q36675912 |
| | Protease inhibitors for the treatment of chronic hepatitis C genotype-1 infection: the new standard of care | Q38014646 |
| | New pharmacotherapy for hepatitis C. | Q38031097 |
| | Genotype and subtype profiling of PSI-7977 as a nucleotide inhibitor of hepatitis C virus | Q39376758 |
| | Recent successes and noteworthy future prospects in the treatment of chronic hepatitis C. | Q39599595 |
| | Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection | Q42989510 |
| P433 | issue | 5 | |
| P921 | main subject | liver cirrhosis | Q147778 |
| | ribavirin | Q421862 |
| | sofosbuvir | Q2502747 |
| | hepatitis C | Q154869 |
| | patient | Q181600 |
| | peginterferon alfa-2a | Q420056 |
| | phase II clinical trial | Q42824440 |
| P304 | page(s) | 401-408 | |
| P577 | publication date | 2013-03-15 | |
| P1433 | published in | Lancet Infectious Diseases | Q15724248 |
| P1476 | title | Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial | |
| P478 | volume | 13 | |